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Abstract
Antigenic drift in the influenza A virus hemagglutinin (HA) is responsible for seasonal reformulation of influenza vaccines.
Here, we address an important and largely overlooked issue in antigenic drift: how does the number and location of
glycosylation sites affect HA evolution in man? We analyzed the glycosylation status of all full-length H1 subtype HA
sequences available in the NCBI influenza database. We devised the ‘‘flow index’’ (FI), a simple algorithm that calculates the
tendency for viruses to gain or lose consensus glycosylation sites. The FI predicts the predominance of glycosylation states
among existing strains. Our analyses show that while the number of glycosylation sites in the HA globular domain does not
influence the overall magnitude of variation in defined antigenic regions, variation focuses on those regions unshielded by
glycosylation. This supports the conclusion that glycosylation generally shields HA from antibody-mediated neutralization,
and implies that fitness costs in accommodating oligosaccharides limit virus escape via HA hyperglycosylation.
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Introduction
The influenza A virus (IAV) hemagglutinin (HA) is a
homotrimeric glycoprotein that initiates infection by attaching
virus to host cell sialic acids and mediating fusion of viral and
endosomal membranes [1]. HA consists of a fibrous stem inserted
into the viral membrane supporting a globular domain containing
three sialic acid binding sites (one per monomer). Trimerization of
nascent HA is necessary for HA folding and export from the early
secretory pathway [2,3,4]. Nearly all antibodies (Abs) that
neutralize viral infectivity (‘‘neutralizing antibodies’’) recognize
epitopes in the globular domain. Most Abs neutralize infection by
sterically blocking access of sialic acid receptors to the HA [5,6].
Neutralizing Abs are the principal selective force driving HA
evolution in man. The rapid emergence of mutants that escape Ab
neutralization is termed ‘‘antigenic drift’’, and has prevented
effective long-term vaccination against IAV. Based on locating
single amino acid substitutions that enable escape from neutral-
ization with monoclonal Abs (mAbs), physically distinct regions
have been defined on the globular domains of H1 (Sa, Sb, Ca, Cb)
and H3 (A, B, C, D, E) subtype HAs [7,8,9]. We term the region of
HA containing these sites, consisting of residues 58–272, the
globular domain. Differences in the location of the antigenic sites
in the globular domain correlate with the differential location of
consensus N-linked oligosaccharide attachment sites in the H1
(PR8) vs. H3 (HK) HAs used for antigenic analysis [9,10].
This raises the important question of the influence of HA
glycosylation on antigenic drift. Other viral glycoproteins (e.g. HIV
gp160) mask potential antigenic sites by hyperglycosylation [11,12].
Addition of glycans to the globular domain has been directly shown
to block neutralization of HA by monoclonal and polyclonal Abs
[13]. Why doesn’t IAV employ this strategy to a greater extent? A
potential clue comes from the distinct evolution of H3 vs. H1 HAsin
humans. Despite circulating for far less time in humans (41 years),
H3 viruses have accumulated approximately twice as many
glycosylation sites in the globular domain than H1 subtype viruses
(circulating for,70years-1918–1957,1977-present)[14,15,16,17].
This is consistent with the idea that there are distinct fitness costs to
glycosylation that vary among HA subtypes [13,18,19,20].
Despite the potential importance of HA glycosylation in IAV
evolution, there is a paucity of bioinformatics analysis of the large
number of sequences accumulating in data banks. Here, we
provide bioinformatics evidence that supports a critical role for
glycosylation in focusing antigenic variation on non-glycosylated
regions of the HA globular domain.
Results
Distribution of N-glycosylation sites in HA sequences
We analyzed 1907 full-length H1 HA sequences from human,
swine or avian viruses downloaded from the NCBI influenza virus
resource. NetNGlyc prediction of glycosylation sites (Asn-Xaa-
Ser/Thr, where Xaa is any amino acid except Pro) in the globular
domain reveals the non-random distribution of probable glycosyl-
ation sites at nine locations (Figure 1a). With few exceptions,
glycosylation sites are located within 5 residues on either side of a
PLoS Pathogens | www.plospathogens.org 1 November 2010 | Volume 6 | Issue 11 | e1001211consensus site. Consequently, for further analysis we defined
conserved glycosylation sites within an 11-residue sequence
centered on the consensus site.
Consistent with previous findings that efficient HA folding and
assembly requires glycosylationat conserved sites, glycosylation sites
at or near residues 15, 26, 289, 483, and 542 occur in virtually all
HAs[4,20,26,27,28,29,30] (note that throughout the manuscript we
use the H3 HA numbering system). These sites are located in the
stem region of the HA (rendered in green in Figure 2) and may be
conserved due to proper association with glycan binding-ER
chaperones that facilitate HA folding and assembly [30]. The
distribution of glycosylation sites in the H1 globular domain is
variable, and is distributed among three regions centered on
residues 91, 129 and 162 are rendered in red (Figure 2). For further
analysis, we chose 65 amino acids on each side of the conserved
glycosylation sites to define glycosylation regions. It is well
documented for H2 HA that addition of consensus glycosylation
sites at these regions results in the predicted glycosylation, as
determined by mobility shifts in SDS-PAGE [13].
Due to their potential influence on antigenic drift, we focused
our attention on the glycosylation sites in the H1 HA globular
domain, which center on residues 91, 129, and 162. We
temporally analyzed the presence of glycosylation sites in viruses
isolated from 1918 to present. Though this analysis is hindered by
the limited number of sequences available until 1995, two trends
are apparent: an increase in glycosylation sites from zero/one as
HA evolved from the 1918 strain to three sites typical for
contemporary H1N1 viruses, and an abrupt reintroduction of a
single glycosylation site with the appearance of SOIV in 2009
(Figure 1b, c). With three glycosylation sites, there are eight
permutations of glycosylation status, all three (1), 2 of 3 (3), one of
three (3), and none (1) (Figure 1d). Our analysis revealed the
complete absence of HAs with glycosylation sites at positions 129
and 162. Interestingly, these sites are essentially adjacent in the 3-
dimensional structure. Thus, it is not surprising that simultaneous
glycosylation would have deleterious effects on HA folding,
providing strong negative selection; what is more surprising that
selection against the two sites is alleviated by a glycosylation site at
residue 91, which is located further down the HA trimer (Figure 2).
Since glycosylation occurs co-translationally, glycosylation at 91
would precede glycosylation at 129/162, and could limit the
extent to which 129 and 162 are simultaneously glycosylated,
accounting for its ability to modulate negative selection against
adjacent sites. Alternatively, the absence of 129 162 dual
glycosylation isolates may relate to historical evolution factors.
Affect of glycosylation on HA evolution
Does glycosylation focus drift on selected antigenic sites? We
correlated the location of glycosylation sites with the variability at
individual residues in the globular domain (Figure 3). This
revealed that glycosylation alters the focus of sequence variation.
In HAs lacking glycosylation sites in the antigenic domain,
variability peaks near residue 135. Acquisition of a glycosylation
site in the same region (129) results in reduction of variability in
that region, and increase in variability at residues 78, 159, and
228, which represent the Cb, Sb, and Ca antigenic sites.
Acquisition of two glycosylation sites at 91 and 129 now focuses
variation at residues 165 and 190. With all three glycosylation sites
utilized, variation is now focused around residues 190 and 191.
Interestingly, positions 190 and 228 greatly influence HA receptor
specificity for a-2,3 vs. a-2,6 of the sialic residue [31,32].
Each combination of glycosylation sites generates a similar
pattern: glycosylation minimizes variation around its own site
while focusing variation onto non-glycosylated sites. The statistical
significance of this conclusion is shown in Figure 4. A simple
interpretation for this finding is that oligosaccharides shield
antigenic regions from Ab neutralization, shifting variation to
unshielded sites. This is consistent with the observation that viruses
cluster in the PCA plot based on a common number of
glycosylation sites in the globular domain and not year of
collection (Figure S2), which demonstrates that they are highly
homologous in the hypervariable regions of the globular domain.
If glycosylation can affect the pattern of antigenic variation, is
there a correlation between number of antigenic domain
glycosylation sites and antigenic variation? There is no clear
relationship between the number of sites and the overall variability
of amino acids between the residues that comprise the globular
domain (58–272) (Figure 1d), indicating that the overall extent of
glycosylation does not globally limit variation in antigenic regions.
We extended this approach to H2N2 and H3N2 HA sequences.
H2N2 viruses possess a single glycosylation site in the globular
domain, located at position 166 (Figure 5a). Consistent with the
H1 data, analysis of H2N2 viruses showed limited variation near
the sole glycosylation site at position 166 (Figure 5b).
H3N2 viruses have up to six glycosylation sites on the globular
domain of HA (Figure 6). When we sorted H3 sequences based on
number of glycosylation sites, we found a distinct trend compared
to H1 HA in acquiring glycosylation sites. Position 168 is the most
conserved position glycosylation in H3 sequences. When there is
one glycosylation, it’s nearly invariably at position 168 (with a few
isolates with lone glycosylation at position 84). Double glycosyl-
ation is dominated by the 84, 168 pairing. Remarkably, triple
gycosylation is dominated by 168 with two novel sites: 66 and 129.
Adding glycosylation at residue 259 uniformly attains four-site
glycosylation. Adding sites between residues 129 and 168 achieve
higher order glycosylation.
We next examined the correlation between the location
glycosylation site and regions of variability for H3 viruses with 2
to 4 sites in the globular domain (Figure 7). Analysis of other
glycoforms was compromised by either paucity of isolates in a group
or by the complexity of glycosylation pattern. Although there was a
reasonable correlation between the presence of a glycosylation site
and absence of variation in the residues surrounding the site, this
Author Summary
Influenza A virus is highly susceptible to neutralizing
antibodies specific for the viral hemagglutinin glycopro-
tein (HA), and is easily controlled by standard vaccines.
Influenza A virus remains an important human pathogen,
however, due to its ability to rapidly evade antibody
responses. This process, termed antigenic drift, is due to
the accumulation of amino acid substitutions that modify
HA antigenic sites recognized by neutralizing antibodies.
In this study, we perform bioinformatic analysis on
thousands of influenza A virus isolates to better under-
stand the influence of N-linked glycosylation on antigenic
drift. HA from human IAV isolates can accommodate up to
6 oligosaccharides in its globular domain. We show that for
H1, H2, and to a somewhat less extent H3, HAs, the
number of glycosylation sites in the globular domain does
not greatly modify the total degree of variation in
antigenic sites, but rather focuses variation on sites
whose access to antibodies is unaffected by glycosylation.
Our findings imply that glycosylation protects HA
from antibody neutralization, but functional impairment
limits the number of oligosaccharides that HA can
accommodate.
Glycan-Modulated Drift
PLoS Pathogens | www.plospathogens.org 2 November 2010 | Volume 6 | Issue 11 | e1001211Figure 1. Distributions of the number and variability of glycosylation sites. a) Distribution of glycosylation sites in HA sequences of H1N1 viruses.
Each bar corresponds to the number of sequences with a glycosylation site at that position. Numbers on the top of the bars show the positions that tend to be more
glycosylated. b) Distribution by years of the percentage of sequences that have 1, 2 or 3 glycosylation sites at the globular domain of HA (percentage). c) Distribution by
years of the percentage of sequences that have 1, 2 or 3 glycosylation sites at the globular domain of HA (absolute values). d) Mean amino acids variability (quantitated
by counting the number of different amino acids found at each position) +/2standard deviation in sequences with three glycosylation sites at the globular domain at
positions 91,129,162, combinations of glycosylation sites of these three positions (there are no sequences with the combination of glycosylation sites at position 129 and
162), a single glycosylation or no glycosylation sites.
doi:10.1371/journal.ppat.1001211.g001
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PLoS Pathogens | www.plospathogens.org 3 November 2010 | Volume 6 | Issue 11 | e1001211Figure 2. H1N1 HA glycosylation sites. Three-dimensional model of HA asa solid surface viewed from the top and side of the trimeric molecule. Receptor
sialic acid oligosaccharidesassociated withHA are shown in blue. Glycosylation sites are highlighted in green (conserved sites) or red and decoratedwithcomplex
sugar moieties. Patterns of glycosylation at positions 91, 129 and 162 (red) are important in neutralization. The proximity of residues 129 and 162 clearly limits
simultaneous glycosylation at these positions, since steric interference between the oligosaccharides would interfere with folding (zoomed region Z1).
doi:10.1371/journal.ppat.1001211.g002
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PLoS Pathogens | www.plospathogens.org 4 November 2010 | Volume 6 | Issue 11 | e1001211Figure 3. Relationship between amino acid variability and presence of glycosylation sites in H1 globular domain. The plots correspond
to H1 HA with the glycosylation sites indicated on the X-axis. Sequences with 2 glycosylation sites in regions 129 and 162 were not found. Green bars plott h e
number of amino acids present at each position in the group of isolates with specific number of oligosaccharide sites indicated, black lines are the running average
of two neighboring positions. The positions and the number of different amino acid residues in each hypervariable region (in parentheses) are shown in red, i.e.,
those regions that have a variability of 3 standard deviations over the mean value (red line). Number of isolates available for each glycosylation stat: zero sites, 21
isolates; 1 site, position 91, 420 isolates; position 129, 10 isolates;position 162, 4 isolates; 2 sites, positions 91, 129, 34 isolates; 91, 162, 33 isolates; 3 sites, 1118 isolates.
doi:10.1371/journal.ppat.1001211.g003
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PLoS Pathogens | www.plospathogens.org 5 November 2010 | Volume 6 | Issue 11 | e1001211Figure 4. Mean values of variability of H1 globular domain. Mean values of variability at A) non-glycosylated regions of HA globular domain;
B) glycosylation sites that are glycosylation competent (i.e. possess consensus glycosylation sites); C) regions that are glycosylated in HA but lack
glycosylation sequences; D) non-glycosylated regions of HA from sequences with 3 glycosylation sequences. To reconstruct this plot, glycosylated
regions considered positions 91,129 and 162 +/23 amino acids. Confidence intervals estimated by bootstrap of 500 replicates [44]. Schematic
representations of the regions used to calculate mean values of A, B, C and D are shown on right.
doi:10.1371/journal.ppat.1001211.g004
Figure 5. Distribution of glycosylation sites in H2N2 viruses and influence on HA variability. a) Distribution of glycosylation sites in H2N2
viruses as in Figure 1A, 83 full-length sequences were used in this analysis. b) Variability in the globular domain of H2N2 viruses, as in Figure 3.
doi:10.1371/journal.ppat.1001211.g005
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PLoS Pathogens | www.plospathogens.org 6 November 2010 | Volume 6 | Issue 11 | e1001211Figure 6. Distribution of glycosylation sites H3N2 viruses. H3N2 viruses were binned according to the number of glycosylation sites in the
globular domain as indicated. Plotted is the percentage of viruses with glycosylation sites in the position designated. A total of 2791 H3N2 full-length
sequences were used in this analysis.
doi:10.1371/journal.ppat.1001211.g006
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indicated by the arrows pointing to exceptions).
Predicting oligosaccharide evolution
Is it possible to predict the tendency of acquisition of glyco-
sylation sites (losses as well as gains) as a function of likelihood of
mutation of codons present in the glycosylation regions? We
devised a simple algorithm, termed the flow index (FI) to model
glycan site evolution based on the sequences present in the
glycosylation regions of H1N1 viruses with a given oligosaccharide
status. The tendency of mutating to (green arrow) or from (red
arrow) a given glycosylation state is assigned is shown in Figure 8.
Summing the probabilities to and from a given state provides a
measure of the probability of remaining in that state (Table S1).
Despite itssimplicity, thisalgorithmreasonably accuratelyreflects
the prevalence of glycoforms among the H1 isolates in the database.
The most notable exception is the 129+162 glycoform, which is not
represented by any isolate despite having a facile mutational path.
Asnoted above,this maybe dueto the proximity oftheseresiduesin
the folded structure, which may interfere with folding of the
globular domain (Figure 2). This exception points to the
contribution of functional selection in the prevalence of glycoforms.
Unfortunately, we could not calculate a FI for H2 or H3 HA
evolution due to either low number of sequences of viruses in a
given group or the complexity of the glycosylation patterns.
Analysis of SOIV evolution
The recent introduction of SOIV into the human population
offers a unique opportunity to study IAV evolution in humans at
high resolution in real time [33,34,35]. Nearly all of the 212
unique SOIV isolates downloaded on October 12
th 2009 possess
oligosaccharide site at position 91. How does the pattern of
variation of SOIVs compare to human H1 isolates or classic Swine
isolates that also possess a single oligosaccharide site at position 91?
Figure 7. Relationship between amino acid variability and presence of glycosylation sites in H3 globular domain. Variability in the
globular domain of H3N2 viruses as in Figure 3. Arrows point to glycosylation sites that do not limit variability in the adjacent residues.
doi:10.1371/journal.ppat.1001211.g007
Glycan-Modulated Drift
PLoS Pathogens | www.plospathogens.org 8 November 2010 | Volume 6 | Issue 11 | e1001211As seen in Figure 9, despite their limited time in humans,
SOIVs demonstrate a remarkable amount of variation, peaking
around positions 225 and 264, with other hot spots at residues 77
and 135 (Figure 9b). This pattern differs from human H1N1
isolated from 1918 to present (Figure 9c), which show far less
variation at residues 225 and 264 regions while focusing variation
near 77, 135 and 190 regions. Classic swine viruses (Figure 9d)
show a different pattern of variation, focused at residues 147 and
Figure 8. Schematic representation of the flow among the different states of the virus generated by the Flow Index. Each heptagon
representsaglycosylationstateofH1HAsfromhumanvirusesisolateduntilmid-2009(i.e.noSwineoriginHAsarerepresented).Basedonthenumberof
isolates with each glycosylation pattern (show in the Table below as number of sequences), we binned viruses into optimal (red), sub-optimal states
(yellow), transitional (grey) and lone lethal state (black). The different states are connected by red arrows to indicate an increase in the number of
glycosylation from the pre-state to the post-state or green arrows to indicate a decrease in the number of glycosylation sites. Values of arrows indicate
the Flow Index (FI), i.e., the tendency of going from one pre-state to a post-state. Data for figure are provided in Table S1. The net FI acting on each state
is given by the sum of the forces as calculated in the Table below, note that this correlates well with the number of isolates in a given state.
doi:10.1371/journal.ppat.1001211.g008
Glycan-Modulated Drift
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PLoS Pathogens | www.plospathogens.org 10 November 2010 | Volume 6 | Issue 11 | e1001211200 (note that the data shown in Figure 3b include all isolates with
a single glycosylation site at position 91).
We again downloaded available unique full-length SOIV
sequences on March 31
st to examine variability over the course
of six months (Figure 9a). Apart from variability at position 225
and 264, there is a higher variability near position 142 (Sb-site)
that was absent in October.
Can we predict the evolution of SOIV glycoforms using the FI?
FI of the October sequences for loss of oligosaccharide at 91 or
gain at 129 or 162 is each calculated to be zero, i.e. two amino
substitutions are required to insert a glycan at these regions.
Indeed, the sequences downloaded on March 2010 showed a
strong tendency to maintain glycosylation at position 91, though a
few isolates lose glycosylation at 91 (10 isolates) or gain
glycosylation at 162 (5 isolates) [36]. We therefore predict that a
single glycosylation site at position 91 at the antigenic domain will
predominate in SOIV isolates for a prolonged period.
Discussion
It has been known for more than 70 years that IAV, unlike
many viruses, demonstrates significant antigenic variation. The
epidemiological significance of antigenic variation in IAV was
unmistakable from the failure of the 1947 vaccination campaign
[37,38]. Despite considerable effort and significant gains in
understanding HA antigenic structure, much remains to be
learned about how drift occurs in humans. The revolution in
nucleic acid sequencing technology provides enormous opportu-
nities to better understand drift. Here, we utilize the NCBI
influenza resource to examine the relationship between glycosyl-
ation in the HA globular domain and antigenic variation.
The ability of oligosaccharides to sterically block antibody
binding to HA antigenic sites was clearly established with the
original definition of antigenic sites on the HA structure using
mAbs [39,40]. Surprisingly, however, the more global effects of
oligosaccharides on HA evolution have been examined in only a
few publications [17,41,42]. We detect a clear influence of
oligosaccharides in directing the focus of variation to the
established neutralizing antibody binding sites on the H1 and
H2 HAs. We also find a similar pattern among H3 HAs with 2–4
globular domain glycosylation sites, but note exceptions to the
relationship (arrows in Figure 6), that might contribute to the
finding of a prior bioinformatics analysis of H3 isolates that failed
to detect a relationship between glycosylation and the locus of
variability [41]. This potential difference in glycosylation in
shaping HA evolution might be related to a major difference in
H1 vs. H3 HA evolution: while H3 remained in human
populations constantly from its introduction in 1968 until the
present time, after the complete replacement of H1 in 1957 by H2
viruses, it re-appeared in 1977 in the form of the 1950 virus,
almost certainly as a result of a re-introduction from a laboratory
sample.
While there is a tendency towards adding oligosaccharides to
the H1 HA with time, the process is slower than might be
expected. H1 viruses have circulated in humans for at least 80
years in the period between 1918 and present time, yet only
possess 3 globular domain glycosylation sites while H3 HAs have
up to six glycosylation sites in the globular domain.
It is important to note that we have not experimentally established
that antibody pressure is responsible for the influence of oligosac-
charides on variation in the globular domain. Although it seems less
likely, it is possible that oligosaccharides influence HA evolution by
modulating the mutation space of globular domain residues.
We show that the sequence space in the regions of the globular
domain where oligosaccharides can be accommodated appears to
play a surprisingly robust role (since at most, only two amino acid
changes are needed to create a glycosylation site) in influencing the
evolutionary acquisition of additional glycosylation sites. Thus,
although the FI is hampered by historical biases in the number of
isolates collected during the course of IAV evolution in man (and
by alterations in glycosylation that accompany adaptation to
growth in eggs or cultured cells [43]), it nonetheless is able to
predict the prevalence of HA glycoforms in H1N1 isolates. That
the FI is a less than perfect prognosticator is expected, since
sequence space does not completely account for oligosaccharide
evolution. A critical missing factor is the fitness of the various
glycoforms, both in terms of viral replication in the human host,
and also the ability of virus to evade neutralizing antibodies.
Oligosaccharides are well known to influence HA function,
particularly binding to host cell receptors and of course, in
shielding HA from Ab mediated neutralization.
Indeed, the major point of this work is that oligosaccharides
influence HA evolution in antigenic regions. Notably, while the
number of oligosaccharides in the globular domain has little gross
effect on the overall variation (Figure 1d), it focuses variation on
uncovered antigenic epitopes. This supports the idea that glycosyl-
ation is an effective strategy for deflecting neutralizing Abs. Why
then, doesn’t HA simply cover itself with oligosaccharides?
The likely answer is that HA simply can’t block all neutra-
lization sites with oligosaccharides and maintain its function. This
may be a more difficult evolutionary task than it appears at first
glance, since HIV gp160 is the exception among viral receptor
proteins rather than the rule. Perhaps there are yet to be defined
host molecules that recognize hyperglycosylated proteins to limit
this strategy.
Materials and Methods
Source of sequences
A first set of 4781 full length HA sequences (full-length
sequences from all hosts and geographic origins) were downloaded
on June 26
th, 2009 from the influenza virus resource at the
NCBI (http://www.ncbi.nlm.nih.gov/genomes/FLU). These in-
clude 1907 H1N1, 83 H2N2 and 2791 H3N2 sequences. A second
set of 212 swine origin influenza virus (SOIV) H1N1 HA
sequences) was downloaded on 12
th October 2009, followed by
a third set of 1339 full-length SOIV sequence was downloaded on
March 31
st 2010.
Prediction of N-glycosylation sites
The NetNGlyc 1.0 web-server (http://www.cbs.dtu.dk/services
/NetNGlyc) was used to predict N-Glycosylation sites (Asn-Xaa-
Ser/Thr, where Xaa is any amino acid except Pro) of all HA
sequences; a positivewasscoredwhen thejuryreturned a ‘‘+’’ score.
According to NetNGlcy, 76% of positive scored sequons are
Figure 9. Relationship between amino acid variability and presence of glycosylation sites in Swine H1 globular domain. The plots
correspond to a) Swine-origin 2009 H1N1 HA sequences (31
st March, 2010) which has 1 glycosylation site in region 91; b) Swine-origin 2009 H1N1 HA
sequences (12
th October, 2009) which has 1 glycosylation site in region 91; c) Human virus HAs from 1918–2008 with 1 glycosylation site in region 91;
d) Swine virus HA sequences from 1918–2008 with 1 glycosylation site in region 91. The positions and the number of possible amino acids of hyper-
variable regions are shown as in Figure 3.
doi:10.1371/journal.ppat.1001211.g009
Glycan-Modulated Drift
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[21,22,23,24].
Multiple sequence alignment
All HA sequences of H1N1 were aligned in a single common
alignment using the program Muscle [25] with default parameters.
Principal Components Analysis of the amino acid
composition
The amino acids composition of the sequences was used to
perform a multivariate analysis called Principal Components
Analysis (PCA). The PCA analysis of the amino acids composition
was performed using the prcomp function of the R package
(http://www.r-project.org). This analysis performs a decomposi-
tion of the variables, e.g. the abundance of each amino acid (20
variables), into each principal component. The first two compo-
nents of the PCA, showed in the plots 1 and 2, preserve 59% of the
total variability (Figure S2).
Amino acid variability
Amino acid variability was quantitated from position 58
through 272 (globular domain). Figure 3 shows the amount of
variability in H1 HA at each position. Variability was quantitated
by counting the number of different amino acids found at each
position, i.e. a position where all sequences have the same amino
acid, the value of variability is 1, while for example a variability
value of 7 corresponds to a position that have 7 different possible
amino acids. Likewise, variability of H2 HA and some H3 HAs at
each position were calculated (Figure 4 and 6). Regions of the H1
HA globular domain 91, 129 and 162+/25 amino acids were
selected to calculate the Flow Index.
Defining the ‘‘Flow Index’’
H1 HA sequences were sorted based on their glycosylation
status (i.e., Ø; 91; 129; 162; 91,129; 91,162; 91,129,162).
Sequences with the glycosylation sites at positions 129 and 162
were not found. The amino acids frequencies in each aligned
amino acid position of these regions for each starting group were
calculated. Then, using the amino acids frequencies at each
position, a set of 10,000 ‘‘random’’ sequences of each group was
generated. These ‘‘random’’ sequences, which maintain the amino
acids frequencies of the actual sequences, correspond to the initial
‘‘pre-state’’ to run the simulations.
We performed two independent rounds of simulation (flow-
charted in Figure S1). Since the tendency of the virus is to
maintain its glycosylation status, a change in status rarely occurs in
a single round of simulation. The first round (left side Figure S1)
uses the amino acids frequencies of each pre-state. Then, choosing
a position at random in a glycosylation region, an amino acid
substitution based on the amino acid frequencies at the same
position is made (i.e. random substitution guided by the amino
acids frequencies of the pre-state sequence). Using this data set, we
enumerated the number of times that single changes in
glycosylation site number occurred (gain or loss) per 10,000
iterations, and calculated the Pdi, the probability of changing
glycosylation status. In the second simulation round (right side,
Figure S1), repeated rounds of simulation are performed until a
change occurs, resulting in PdiRj the probability of changing from
a pre-state to a post-state that differ by a single glycosylation site
(gain or loss). The Flow Index (FI) is defined as the product of the
two rounds and provides a measure of the tendency of changing
from a pre-state i to a post-state j.
FI~Pdi|Pdi?j|1000
Since the FI is based on the frequency of amino acid of all
sequences in the starting group, it is free of constraints imposed by
a consensus sequence. In addition, the FI also takes selection into
account, since only sequences of viable viruses are used in the
simulated mutagenesis.
Supporting Information
Table S1 Data for FI.
Found at: doi:10.1371/journal.ppat.1001211.s001 (0.06 MB
DOC)
Figure S1 Flow Chart of Flow Index algorithm.
Found at: doi:10.1371/journal.ppat.1001211.s002 (0.65 MB TIF)
Figure S2 Representation of the first and second components of
the Principal Components Analysis (PCA) for H1 viruses. PCA of
the amino acids composition of H1N1. The first two components
of the PCA account for 59% of the total variability. a) PCA plot by
host. Blue diamonds correspond to sequences found in avian
viruses, green triangles correspond to sequences found in swine
viruses, and red squares correspond to sequences found in human
viruses. b) PCA plot by number of glycosylation sites. Red squares
correspond to sequences without glycosylation sites, blue dia-
monds correspond to sequences with 1 glycosylation site, green
triangles correspond to sequences with 2 glycosylation sites, purple
crosses correspond to sequences with 3 glycosylation sites and light
blue stars correspond to sequences with 4 glycosylation sites in the
globular domain. c) Distribution of the values of the first
component (PC1) by years. Blue bars correspond to sequences
found in avian viruses, green bars correspond to sequences found
in swine viruses, and red bars correspond to sequences found in
human viruses. d) Distribution of the values of the second
component (PC2) by years. Blue bars correspond to sequences
found in avian viruses, green bars correspond to sequences found
in swine viruses, and red bars correspond to sequences found in
human viruses.
Found at: doi:10.1371/journal.ppat.1001211.s003 (1.13 MB TIF)
Author Contributions
Conceived and designed the experiments: SRD PP JRB JWY. Performed
the experiments: SRD PP. Analyzed the data: SRD PP SEH DEH JRB
JWY. Contributed reagents/materials/analysis tools: SRD PP DEH.
Wrote the paper: SRD PP SEH JRB JWY.
References
1. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus
entry: the influenza hemagglutinin. Annu Rev Biochem 69: 531–569.
2. Russ G, Bennink JR, Bachi T, Yewdell JW (1991) Influenza virus hemagglutinin
trimers and monomers maintain distinct biochemical modifications and
intracellular distribution in brefeldin A-treated cells. Cell Regul 2: 549–563.
3. Yewdell JW, Yellen A, Bachi T (1988) Monoclonal antibodies localize events in
the folding, assembly, and intracellular transport of the influenza virus
hemagglutinin glycoprotein. Cell 52: 843–852.
4. Daniels R, Kurowski B, Johnson AE, Hebert DN (2003) N-linked glycans direct the
cotranslational folding pathway of influenza hemagglutinin. Mol Cell 11: 79–90.
5. Wilson IA, Skehel JJ, Wiley DC (1981) Structure of the haemagglutinin
membrane glycoprotein of influenza virus at 3 A resolution. Nature 289:
366–373.
6. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody-
binding sites of Hong Kong influenza haemagglutinin and their involvement in
antigenic variation. Nature 289: 373–378.
Glycan-Modulated Drift
PLoS Pathogens | www.plospathogens.org 12 November 2010 | Volume 6 | Issue 11 | e10012117. Gerhard W, Yewdell J, Frankel ME, Webster R (1981) Antigenic structure of
influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290:
713–717.
8. Yewdell JW, Gerhard W (1981) Antigenic characterization of viruses by
monoclonal antibodies. Annu Rev Microbiol 35: 185–206.
9. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic
structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell
31: 417–427.
10. Wiley DC, Skehel JJ (1987) The structure and function of the hemagglutinin
membrane glycoprotein of influenza virus. Annual Reviews in Biochemistry 56:
365–394.
11. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, et al. (2004) Tracking
global patterns of N-linked glycosylation site variation in highly variable viral
glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin.
Glycobiology 14: 1229–1246.
12. Vigerust DJ, Shepherd VL (2007) Virus glycosylation: role in virulence and
immune interactions. Trends Microbiol 15: 211–218.
13. Tsuchiya E, Sugawara K, Hongo S, Matsuzaki Y, Muraki Y, et al. (2002) Effect
of addition of new oligosaccharide chains to the globular head of influenza A/
H2N2 virus haemagglutinin on the intracellular transport and biological
activities of the molecule. J Gen Virol 83: 1137–1146.
14. Schulze IT (1997) Effects of glycosylation on the properties and functions of
influenza virus hemagglutinin. J Infect Dis 176 Suppl 1: S24–28.
15. Mir-Shekari SY, Ashford DA, Harvey DJ, Dwek RA, Schulze IT (1997) The
glycosylation of the influenza A virus hemagglutinin by mammalian cells. A site-
specific study. J Biol Chem 272: 4027–4036.
16. Igarashi M, Ito K, Kida H, Takada A (2008) Genetically destined potentials for
N-linked glycosylation of influenza virus hemagglutinin. Virology 376: 323–329.
17. Cherry JL, Lipman DJ, Nikolskaya A, Wolf YI (2009) Evolutionary dynamics of
N-glycosylation sites of influenza virus hemagglutinin. PLoS Curr Influenza. pp
RRN1001.
18. Deshpande KL, Fried VA, Ando M, Webster RG (1987) Glycosylation affects
cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence.
Proc Natl Acad Sci U S A 84: 36–40.
19. Wang CC, Chen JR, Tseng YC, Hsu CH, Hung YF, et al. (2009) Glycans on
influenza hemagglutinin affect receptor binding and immune response. Proc
Natl Acad Sci U S A 106: 18137–18142.
20. Wagner R, Heuer D, Wolff T, Herwig A, Klenk HD (2002) N-Glycans attached
to the stem domain of haemagglutinin efficiently regulate influenza A virus
replication. J Gen Virol 83: 601–609.
21. Ben-Dor S, Esterman N, Rubin E, Sharon N (2004) Biases and complex patterns
in the residues flanking protein N-glycosylation sites. Glycobiology 14: 95–101.
22. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR (2004) Statistical
analysis of the protein environment of N-glycosylation sites: implications for
occupancy, structure, and folding. Glycobiology 14: 103–114.
23. Breuer W, Klein RA, Hardt B, Bartoschek A, Bause E (2001) Oligosacchar-
yltransferase is highly specific for the hydroxy amino acid in Asn-Xaa-Thr/Ser.
FEBS Lett 501: 106–110.
24. Kasturi L, Eshleman JR, Wunner WH, Shakin-Eshleman SH (1995) The
hydroxy amino acid in an Asn-X-Ser/Thr sequon can influence N-linked core
glycosylation efficiency and the level of expression of a cell surface glycoprotein.
J Biol Chem 270: 14756–14761.
25. Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy
and high throughput. Nucleic Acids Res 32: 1792–1797.
26. Gallagher PJ, Henneberry JM, Sambrook JF, Gething MJ (1992) Glycosylation
requirements for intracellular transport and function of the hemagglutinin of
influenza virus. J Virol 66: 7136–7145.
27. Gallagher P, Henneberry J, Wilson I, Sambrook J, Gething MJ (1988) Addition
of carbohydrate side chains at novel sites on influenza virus hemagglutinin can
modulate the folding, transport, and activity of the molecule. J Cell Biol 107:
2059–2073.
28. Klenk HD, Wagner R, Heuer D, Wolff T (2002) Importance of hemagglutinin
glycosylation for the biological functions of influenza virus. Virus Res 82: 73–75.
29. Ohuchi R, Ohuchi M, Garten W, Klenk HD (1997) Oligosaccharides in the
stem region maintain the influenza virus hemagglutinin in the metastable form
required for fusion activity. J Virol 71: 3719–3725.
30. Hebert DN, Foellmer B, Helenius A (1996) Calnexin and calreticulin promote
folding, delay oligomerization and suppress degradation of influenza hemagglu-
tinin in microsomes. EMBO J 15: 2961–2968.
31. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006)
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza
virus. Science 312: 404–410.
32. Nicholls JM, Chan RW, Russell RJ, Air GM, Peiris JS (2008) Evolving
complexities of influenza virus and its receptors. Trends Microbiol 16: 149–157.
33. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic
and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses
circulating in humans. Science 325: 197–201.
34. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in
vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:
1021–1025.
35. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of
swine-origin H1N1 influenza virus. Nature 459: 931–939.
36. Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, et al. Cross-
neutralization of 1918 and 2009 influenza viruses: role of glycans in viral
evolution and vaccine design. Sci Transl Med 2: 24ra21.
37. Francis T, Salk JE, Quilligan JJ (1947) Experience with Vaccination Against
Influenza in the Spring of 1947: A Preliminary Report. Am J Public Health
Nations Health 37: 1013–1016.
38. Francis T, Jr. (1947) Apparent serological variation within a strain of influenza
virus. Proc Soc Exp Biol Med 65: 143–147.
39. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, et al. (1984) A
carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses
inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 81:
1779–1783.
40. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Jr., et al. Structural Basis of
Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. Science.
41. Blackburne BP, Hay AJ, Goldstein RA (2008) Changing selective pressure
during antigenic changes in human influenza H3. PLoS Pathog 4: e1000058.
42. Tamuri AU, Dos Reis M, Hay AJ, Goldstein RA (2009) Identifying changes in
selective constraints: host shifts in influenza. PLoS Comput Biol 5: e1000564.
43. Gambaryan AS, Robertson JS, Matrosovich MN (1999) Effects of egg-
adaptation on the receptor-binding properties of human influenza A and B
viruses. Virology 258: 232–239.
44. Wessa P (2008) Bootstrap Plot for Central Tendency (v1.0.3) in Free Statistics
Software (v1.1.23-r6), Office for Research Development and Education. URL
http://www.wessa.net/rwasp_bootstrapplot1.wasp/.
Glycan-Modulated Drift
PLoS Pathogens | www.plospathogens.org 13 November 2010 | Volume 6 | Issue 11 | e1001211